RaQualia Pharma Inc.
RaQualia Pharma Inc. scores highest on Earnings (58) and lowest on Price (20). Its PosiPenta is 33.16 out of 100, weaker than most similar companies.
On the Penta Grid this week, RaQualia Pharma Inc. is Grid #50 of 53 in the Healthcare sector in Japan, and Grid #985 of 1,059 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| RaQualia Pharma Inc. | 33.16 | 20 | 58 | 23 | 35 | 30 |
| Japan Medical Dynamic Marketing, INC. | 36.57 | 47 | 53 | 24 | 25 | 34 |
| HYUGA PRIMARY CARE Co.,Ltd. | 56.04 | 17 | 65 | 100 | 56 | 43 |
| Fuso Pharmaceutical Industries,Ltd. | 66.50 | 95 | 91 | 50 | 34 | 64 |
| Ohki Healthcare Holdings Co.,Ltd. | 46.77 | 69 | 50 | 24 | 29 | 61 |
| Kusurinomadoguchi, Inc. | 63.94 | 62 | 94 | 27 | 72 | 64 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | 71.31 |
| P/B ratio | 2.07 |
EEarnings
| Trailing EPS | ₹5.30 |
| Forward EPS | ₹15.80 |
NNitro
| Price | 377.75 |
| 52-week high | 886.86 |
| 52-week low | 265.15 |
| Fall from 52-week high | 57.4% |
TTorque
| Return on equity (ROE) | 2.28% |
| Debt-to-equity | 0.34 |
AAnchor
| Beta (price swings) | 0.87 |
| Market cap | ₹983 Cr |
| Insider holding | 31.65% |
| Dividend yield | 0.00% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is RaQualia Pharma Inc.'s PosiPenta score?
RaQualia Pharma Inc.'s PosiPenta is 33.16 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does RaQualia Pharma Inc. stand on the Penta Grid?
On the Penta Grid this week, RaQualia Pharma Inc. is Grid #50 of 53 in the Healthcare sector in Japan, and Grid #985 of 1,059 in Japan.
Which PosiPenta pillar is strongest for RaQualia Pharma Inc.?
Earnings (growth), with a score of 58 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for RaQualia Pharma Inc.?
Price (valuation), with a score of 20 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.